comparing cardiovascular and kidney outcomes with tirzepatide vs. glp-1 agonists Bridging the gap between GLP1-receptor outcomes: evidence for the role of | Cardiovascular Diabetology Frontiers | Clinical perspectives on

In fact, people have achieved such dramatic weight loss on retatrutide that experts are talking about the drug as a potential competitor to bariatric surgery

10.1097/aln.0000000000004381

Patients should avoid choosing a medication based only on headline weight-loss percentages

Recommendation 2 advises proactive measures to reduce aspiration risk: preoperative liquid diet for at least 24 h

Let's talk about you next

Whether you have health insurance or not, heres the latest on how to potentially access GLP-1s: Paying out of pocket without insurance The Trump Administration is taking steps to make it more affordable for people without insurance, including from any state, government or federally funded program, to access GLP-1s through TrumpRx.gov